Saxon Emma
BMC Biology, BioMed Central, 236 Gray's Inn Road, London, WC1X 8HB, UK.
BMC Biol. 2015 Aug 29;13:68. doi: 10.1186/s12915-015-0181-x.
Virus B is a newly emerged viral strain for which there is no current treatment. Drug A was identified as a potential treatment for infection with virus B. In this pre-clinical phase of drug testing, the effects of drug A on survival after infection with virus B was tested. There was no difference in survival between control (dark blue) and drug A-treated, virus B-infected mice (green), but a significant difference in survival between control and virus B-infected mice without drug treatment (light blue, z-test for proportions P < 0.05, n = 30 in each group). The authors therefore concluded that drug A is effective in reducing mouse mortality due to virus B.
病毒B是一种新出现的病毒株，目前尚无治疗方法。药物A被确定为治疗病毒B感染的潜在药物。在药物测试的临床前阶段，测试了药物A对感染病毒B后存活率的影响。对照组（深蓝色）和接受药物A治疗且感染病毒B的小鼠（绿色）之间的存活率没有差异，但对照组和未接受药物治疗的感染病毒B的小鼠（浅蓝色）之间的存活率存在显著差异（比例的z检验，P < 0.05，每组n = 30）。因此，作者得出结论，药物A可有效降低病毒B导致的小鼠死亡率。
